Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies

Fuso Pharmaceutical announced on December 9 that the company withdrew on the same day a new drug application (NDA) for its investigational adhesive patch for oral use FTB-8127 (buprenorphine) in Japan for the treatment of postherpetic neuralgia (PHN), which was...read more